Defining Vasoplegia Following Durable, Continuous Flow Left Ventricular Assist Device Implantation
- PMID: 34227791
- DOI: 10.1097/MAT.0000000000001419
Defining Vasoplegia Following Durable, Continuous Flow Left Ventricular Assist Device Implantation
Abstract
This study aimed to develop a definition of vasoplegia that reliably predicts clinical outcomes. Vasoplegia was evaluated using data from the electronic health record for each 15-minute interval for 72 hours following cardiopulmonary bypass. Standardized definitions considered clinical features (systemic vascular resistance [SVR], mean arterial pressure [MAP], cardiac index [CI], norepinephrine equivalents [NEE]), threshold strategy (criteria occurring in any versus all measurements in an interval), and duration (criteria occurring over multiple consecutive versus separated intervals). Minor vasoplegia was MAP < 60 mm Hg or SVR < 800 dynes⋅sec⋅cm-5 with CI > 2.2 L/min/m2 and NEE ≥ 0.1 µg/kg/min. Major vasoplegia was MAP < 60 mm Hg or SVR < 700 dynes⋅sec⋅cm-5 with CI > 2.5 L/min/m2 and NEE ≥ 0.2 µg/kg/min. The primary outcome was incidence of vasoplegia for eight definitions developed utilizing combinations of these criteria. Secondary outcomes were associations between vasoplegia definitions and three clinical outcomes: time to extubation, time to intensive care unit discharge, and nonfavorable discharge. Minor vasoplegia detected anytime within a 15-minute period (MINOR_ANY_15) predicted the highest incidence of vasoplegia (61%) and was associated with two of three clinical outcomes: 1 day delay to first extubation (95% CI: 0.2 to 2) and 7 day delay to first intensive care unit discharge (95% CI: 1 to 13). The MINOR_ANY_15 definition should be externally validated as an optimal definition of vasoplegia.
Copyright © ASAIO 2021.
Conflict of interest statement
Dr. Swan received research funding from La Jolla Pharmaceutical Company to support fellowship training for Dr. Rizk and Dr. Iso. Dr. Masud is a paid member of the advisory board for the La Jolla Pharmaceutical Company. The authors do not have any conflicts of interest to report.
References
-
- Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG: Definitions and pathophysiology of vasoplegic shock. Crit Care. 22: 174, 2018.
-
- Omar S, Zedan A, Nugent K: Cardiac vasoplegia syndrome: Pathophysiology, risk factors and treatment. Am J Med Sci. 349: 80–88, 2015.
-
- Fischer GW, Levin MA: Vasoplegia during cardiac surgery: Current concepts and management. Semin Thorac Cardiovasc Surg. 22: 140–144, 2010.
-
- Levy B, Fritz C, Tahon E, Jacquot A, Auchet T, Kimmoun A: Vasoplegia treatments: The past, the present, and the future. Crit Care. 22: 52, 2018.
-
- Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J: Low systemic vascular resistance after cardiopulmonary bypass: Incidence, etiology, and clinical importance. J Card Surg. 15: 347–353, 2000.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources